Scholarlink

Introduction <p>Community-acquired pneumonia (CAP) continues to be a major worldwide health problem, especially for immunocompromised individuals and the elderly.</p> Methodology <p>Diagnostic methods include radiological, microbiological, and molecular testing, as well as clinical examination.</p> Results <p>Appropriate antibiotic medication, prompt diagnosis, and identification of the causing microorganisms are essential for effective care. <i>Streptococcus pneumoniae</i>, <i>Haemophilus influenzae</i>, and atypical bacteria are common etiological agents. Since β-lactams, macrolides, and fluoroquinolones are often utilized, empirical antibiotic treatment that is informed by local resistance trends is essential. Tools for risk assessment, such as PSI and CURB-65, help with therapy choices.</p> Conclusion <p>In order to improve CAP results and lower mortality, more research is needed on novel medicines, resistance patterns, and quick diagnoses.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A Comprehensive Review of the Epidemiology, Diagnostics, and Clinical Strategy for Community-Acquired Pneumonia

  • 期刊论文

  • 发表日期：

    2025年8月15日

查看全文
  • Jayanta Deb,
  • Saurabh Gupta,
  • Saheli Bhadra,
  • Sanjit Debnath

摘要

Introduction

Community-acquired pneumonia (CAP) continues to be a major worldwide health problem, especially for immunocompromised individuals and the elderly.

Methodology

Diagnostic methods include radiological, microbiological, and molecular testing, as well as clinical examination.

Results

Appropriate antibiotic medication, prompt diagnosis, and identification of the causing microorganisms are essential for effective care. Streptococcus pneumoniae, Haemophilus influenzae, and atypical bacteria are common etiological agents. Since β-lactams, macrolides, and fluoroquinolones are often utilized, empirical antibiotic treatment that is informed by local resistance trends is essential. Tools for risk assessment, such as PSI and CURB-65, help with therapy choices.

Conclusion

In order to improve CAP results and lower mortality, more research is needed on novel medicines, resistance patterns, and quick diagnoses.